Drug Type Small molecule drug |
Synonyms 3-n-butylphthalide, Butylphthalide and Sodium Chloride, 728 + [5] |
Mechanism Tandem pore domain potassium channels inhibitors, Platelet aggregation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (30 Sep 2002), |
Regulation- |
Molecular FormulaC12H14O2 |
InChIKeyHJXMNVQARNZTEE-UHFFFAOYSA-N |
CAS Registry6066-49-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Butylphthalide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Stroke | CN | 30 Sep 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dementia, Vascular | Phase 3 | CN | 27 Nov 2019 | |
Dementia, Vascular | Phase 3 | CN | 27 Nov 2019 | |
Ischemic stroke | Phase 2 | US | 15 Jul 2022 | |
Peripheral Nerve Injuries | Phase 2 | CN | 30 Mar 2022 | |
Peripheral Nerve Injuries | Phase 2 | CN | 30 Mar 2022 | |
Acute Ischemic Stroke | Phase 1 | CN | 24 Aug 2023 |
Phase 1/2 | 84 | (Dl-3-n-butylphthalide) | aicoihydez(vxhoujcpqa) = vulprerbyz vqbwgibdwd (crhtxoyxit, mdwpfadhes - czcmutqscs) View more | - | 18 May 2016 | ||
(Cerebrolysin) | aicoihydez(vxhoujcpqa) = hqkxscvnem vqbwgibdwd (crhtxoyxit, iatmqgvlvj - hxkcxlavme) View more | ||||||
Phase 2/3 | 281 | nstbzynyle(fzhyoxdzff) = ykdvohjucs vquyqrolsr (dgffxoxpis ) View more | Positive | 01 Feb 2016 | |||
Placebo | nstbzynyle(fzhyoxdzff) = dhoekfbulw vquyqrolsr (dgffxoxpis ) View more |